Liarozole HCl is a benzimidazole derivative with antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits CYP450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, leading to an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. It also inhibits aromatase.

145858-50-0

C17H14Cl2N4

345.23

R75251;R 75251;Liarozole hydrochloride;R-75251;Liarozole HCl

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years